Analogs of deutetrabenazine, their preparation and use

Abstract

The disclosure is directed to deutetrabenazine analogs, compositions comprising same and methods of detecting same in compositions comprising deutetrabenazine.

What is claimed is: 
     
         1 . Deutetrabenazine drug substance comprising Compound 2 in an amount that is about 0.15 area-% or less of Compound 2, relative to the concentration of the deutetrabenazine, based on a determination by an HPLC method comprising a C18, 150×4.6 mm, 3.5 m column and a photodiode array/ultraviolet detector at 220 nm. 
       
         
           
           
               
               
           
         
       
     
     
         2 . The deutetrabenazine drug substance of  claim 1 , comprising about 0.05 area-% to about 0.15 area-% of Compound 2, relative to the concentration of the deutetrabenazine. 
     
     
         3 . The deutetrabenazine drug substance of  claim 1 , comprising about 0.05 area-% to about 0.1 area-% of Compound 2, relative to the concentration of the deutetrabenazine. 
     
     
         4 . The deutetrabenazine drug substance of  claim 1 , comprising about 0.15 area-% of Compound 2, relative to the concentration of the deutetrabenazine. 
     
     
         5 . The deutetrabenazine drug substance of  claim 1 , comprising about 0.1 area-% of Compound 2, relative to the concentration of the deutetrabenazine. 
     
     
         6 . The deutetrabenazine drug substance of  claim 1 , comprising about 0.05 area-% of Compound 2, relative to the concentration of the deutetrabenazine. 
     
     
         7 . The deutetrabenazine drug substance  claim 1 , wherein the deutetrabenazine has a deuterium enrichment of no less than about 50%. 
     
     
         8 . The deutetrabenazine drug substance of  claim 1 , wherein the deutetrabenazine has a deuterium enrichment of no less than about 90%. 
     
     
         9 . The deutetrabenazine drug substance of  claim 1 , wherein the deutetrabenazine has a deuterium enrichment of no less than about 95%. 
     
     
         10 . The deutetrabenazine drug substance of  claim 1 , wherein the deutetrabenazine has a deuterium enrichment of no less than about 98%. 
     
     
         11 . The deutetrabenazine drug substance of  claim 1 , wherein the Compound 2 has a deuterium enrichment of no less than about 50%. 
     
     
         12 . The deutetrabenazine drug substance of  claim 1 , wherein the Compound 2 has a deuterium enrichment of no less than about 90%. 
     
     
         13 . The deutetrabenazine drug substance of  claim 1 , wherein the Compound 2 has a deuterium enrichment of no less than about 95%. 
     
     
         14 . The deutetrabenazine drug substance of  claim 1 , wherein the Compound 2 has a deuterium enrichment of no less than about 98%. 
     
     
         15 . A method of producing a deutetrabenazine drug product comprising:
 a. obtaining the deutetrabenazine drug substance of  claim 1 ;   b. admixing the deutetrabenazine drug substance with one or more suitable excipient.   
     
     
         16 . A process for determining the amount of Compound 2 in the deutetrabenazine drug substance of  claim 1  comprising:
 a. obtaining the deutetrabenazine drug substance; 
 b. determining the amount of the Compound 2 in the deutetrabenazine drug substance, based on a determination by the HPLC method.